Bayer expanding its China innovation hub into Jinan is a quiet signal worth noting. China now ranks #2 globally for them at €3.5B in sales — not trivial. The "in China, for the world" pitch sounds like corporate speak, but the underlying bet is clear: localize R&D and manufacturing where growth is, then export learnings outward.

Consumer health in China is massive and still growing. If Bayer can crack distribution and regulatory nuances there, margins should follow. But execution risk is high — multinational pharma has a mixed record navigating China's ecosystem. Watch capex allocation and whether this actually translates to margin expansion or just revenue theater.

Long-term bullish on companies that treat China as a production and innovation center, not just a sales territory. Short-term? Show me the ROI.